Tonix Pharmaceuticals (TNXP) News Today → Stock-Picking AI Predicts #1 Stock of 2024 (From Altimetry) (Ad) Free TNXP Stock Alerts $0.18 +0.01 (+5.76%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - May 5 at 2:44 AMAnalysts Issue Forecasts for Tonix Pharmaceuticals Holding Corp.'s Q2 2024 Earnings (NASDAQ:TNXP)americanbankingnews.com - May 2 at 1:24 AMZacks Small Cap Comments on Tonix Pharmaceuticals Holding Corp.'s Q1 2024 Earnings (NASDAQ:TNXP)americanbankingnews.com - May 1 at 1:16 AMTNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025…msn.com - April 29 at 2:02 PMTonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcaseglobenewswire.com - April 24 at 8:00 AMTonix Pharmaceuticals Holding (TNXP) Price Target Decreased by 37.78% to 3.57msn.com - April 17 at 9:46 AM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsglobenewswire.com - April 1 at 4:15 PMTonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?msn.com - April 1 at 11:54 AMLatest News for Tonix Pharmaceuticals Stock (NASDAQ:TNXP)benzinga.com - March 30 at 10:49 AMWhy Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliteratedbenzinga.com - March 28 at 2:08 PMTonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offeringglobenewswire.com - March 28 at 9:32 AMTonix Pharma's TNX-2900 Gets Rare Pediatric Disease Designation For Prader-Willi Syndromemarkets.businessinsider.com - March 25 at 12:11 PMTonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndromeglobenewswire.com - March 25 at 8:00 AM3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Millioninvestorplace.com - March 24 at 4:05 PMTonix Pharmaceuticals Holding Corpmorningstar.com - March 22 at 5:04 PMTonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meetingfinance.yahoo.com - March 21 at 10:38 AMTonix picks CMOs for potential launch of fibromyalgia drugmsn.com - March 20 at 7:36 PMTonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024globenewswire.com - March 19 at 8:00 AMTNXP: Tonmya™ May Launch Alongside Another New Fibromyalgia Treatment…finance.yahoo.com - March 12 at 1:02 PMTonix Pharmaceuticals Announces Presentation at BIO-Europe Springglobenewswire.com - March 12 at 8:00 AMTonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgiafinance.yahoo.com - March 11 at 9:49 AMTonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapyglobenewswire.com - March 7 at 8:00 AMTonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgiafinance.yahoo.com - March 6 at 4:48 PMTonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humansfinance.yahoo.com - March 5 at 8:35 AMDawson James Initiates Coverage of Tonix Pharmaceuticals Holding (TNXP) with Buy Recommendationmsn.com - February 29 at 1:52 PMTonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trialfinance.yahoo.com - February 28 at 8:18 AMTonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteersfinance.yahoo.com - February 28 at 8:18 AMTonix Pharma Plans Regulatory Filings For Tonmya In Japan, China, US; Stock Upmarkets.businessinsider.com - February 27 at 10:28 AMTonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and Chinafinance.yahoo.com - February 27 at 10:28 AMNew Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Painfinance.yahoo.com - February 26 at 8:07 AM3 Top Penny Stocks for 5,000% Upside in 2024 and Beyondinvestorplace.com - February 25 at 2:12 PMNew to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Seriesfinance.yahoo.com - February 23 at 9:40 AMTonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentationproactiveinvestors.com - February 23 at 12:54 AMTonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defence funded trialproactiveinvestors.com - February 20 at 1:26 PMTonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conferencefinance.yahoo.com - February 20 at 8:26 AMTonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 20 at 8:00 AMACXP Mar 2024 3.000 putfinance.yahoo.com - February 17 at 6:56 AMNew to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PTfinance.yahoo.com - February 16 at 12:39 PMTonix Pharmaceuticals: Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addictionfinanznachrichten.de - February 15 at 10:53 AMTonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addictionfinance.yahoo.com - February 15 at 10:53 AMTonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024finance.yahoo.com - February 14 at 8:20 AMTonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024globenewswire.com - February 14 at 8:00 AMTonix stock climbs 9% after FDA approves PTSD studymsn.com - February 12 at 7:10 PMTonix Drug Shown To Relieve Pain in Fibromyalgia Without Getting Patients Addicted In Phase 3 Trialbenzinga.com - February 9 at 8:43 AMTonix Pharma Discloses COPCs Linked to Long COVID Riskmsn.com - February 2 at 10:09 AMTonix Pharma Examines COPCs Impact on Long COVID Risksmsn.com - February 1 at 7:43 AMTonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVIDfinance.yahoo.com - January 31 at 9:45 AM20 Countries With The Highest Number of Drug Trafficking in the Worldfinance.yahoo.com - January 30 at 6:41 PMTonix Pharma’s TNX-102 SL Receives Conditional FDA Nodmsn.com - January 30 at 1:40 PM Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. TNXP Media Mentions By Week TNXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNXP News Sentiment▼0.950.42▲Average Medical News Sentiment TNXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNXP Articles This Week▼102▲TNXP Articles Average Week Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Avalo Therapeutics News NanoViricides News MIRA Pharmaceuticals News RedHill Biopharma News Imunon News Purple Biotech News ABVC BioPharma News Edesa Biotech News AgeX Therapeutics News NeuroBo Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNXP) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe only accurate crypto trading system I know …Weiss RatingsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
